PhoreMost Announces Lead Oncology Programme and Appoints Chief Medical Officer to Support Clinical Entry
· Next-generation small molecule microtubule targeting agent, PMC-001, progressing towards Phase 1
· Comprehensive preclinical data package demonstrates differentiating oral activity and CNS penetration, unlocking treatment of primary and secondary brain cancers
· Dr Gabriel Fox appointed as Chief Medical Officer to lead clinical development